Algorae Pharmaceuticals Ltd (ASX:1AI, OTC:LVCLF, FRA:LHI0) has completed the prediction-generation phase of a multi-anchor drug combination program using its AlgoraeOS v2 (AOS2) artificial intelligence platform.
The program expands AOS2 from a single-anchor approach, previously centred on cannabidiol, to 18 anchor drugs, materially broadening the company’s pipeline of AI-predicted drug combination opportunities.
AOS2 evaluated more than nine million potential drug-drug-cell line combinations, pairing 18 anchor drugs with thousands of approved and investigational compounds across a panel of human cell lines.
The 18 anchor drugs were selected to span a range of therapeutic areas and mechanisms of action, giving Algorae optionality across multiple disease contexts.
Each prediction included four recognised synergy metrics — ZIP, Bliss, HSA and Loewe — alongside confidence-weighted measures of predictive uncertainty.
Initial filtering identifies 6,000-plus combinations
Initial filtering identified more than 478,000 individual synergy predictions that passed preliminary synergy and uncertainty thresholds.
From this pool, more than 6,000 drug combinations demonstrated predicted synergy across multiple cell lines, which the company said indicated greater biological robustness.
Algorae said the larger scale of the multi-anchor program would now require further curation using anchor-specific considerations, including predicted strength and consistency of synergy, biological robustness, novelty relative to existing empirical data, and commercial and intellectual property relevance.
Next phase to produce shortlist
The next step is to develop a high-priority shortlist of candidates for potential progression into preclinical validation.
Shortlisted candidates are expected to inform Algorae’s ongoing discussions with the Peter MacCallum Cancer Centre regarding independent validation and a previously announced second program, which is now underway.
Chief scientific officer Dr James McKenna said the program demonstrated AOS’s in silico predictive capability through the rapid generation of large-scale predictions across approved and investigational drugs with diverse mechanisms of action.
“This program provides a compelling demonstration of the in silico predictive capability of AOS through the rapid generation of large-scale predictions across approved and investigational drugs with diverse mechanisms of action. In doing so, the program has dramatically expanded the company’s pool of candidate drug combinations for further evaluation, while reducing reliance on traditional, resource-intensive screening methods.”
About Algorae
Algorae is an AI-enabled pharmaceutical company focused on drug-combination discovery and pharmaceutical commercialisation.
Its proprietary AlgoraeOS platform uses machine learning and deep neural networks to identify synergistic drug combinations and support dose selection for preclinical development.
Alongside its AI drug discovery work, Algorae operates AlgoraeRx, a commercialisation business that sources, licenses and supplies generic and specialty medicines in Australia and New Zealand through partnered manufacturers and established distribution channels.